UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma

Haematologica (Roma), 2013-07, Vol.98 (7), p.1132-1141

2013

Volltextzugriff (PDF)

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement

Clinical cancer research, 2016-09, Vol.22 (17), p.4341-4349

2016

Volltextzugriff (PDF)

Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma

Blood cancer journal (New York), 2024-09, Vol.14 (1), p.156-11, Article 156

2024

Volltextzugriff (PDF)

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS

Haematologica (Roma), 2020-09, Vol.105 (9), p.2316-2326

2020

Volltextzugriff (PDF)

Efficient transient transfection of human multiple myeloma cells by electroporation--an appraisal

PloS one, 2014-06, Vol.9 (6), p.e97443-e97443

2014

Volltextzugriff (PDF)

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma

Blood cancer journal (New York), 2021-03, Vol.11 (3), p.51-51, Article 51

2021

Volltextzugriff (PDF)

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

Blood, 2011-02, Vol.117 (6), p.1998-2004

2011

Volltextzugriff (PDF)

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma

Blood cancer journal (New York), 2023-03, Vol.13 (1), p.43-43, Article 43

2023

Volltextzugriff (PDF)

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines

Cancers, 2020-02, Vol.12 (2), p.455

2020

Volltextzugriff (PDF)

JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen

TumorDiagnostik & Therapie, 2021-04, Vol.42 (3), p.176-184

2021

Volltextzugriff (PDF)

JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen

Aktuelle Rheumatologie, 2020-12, Vol.45 (6), p.559-567

2020

Volltextzugriff (PDF)

Multiples Myelom – dynamische Entwicklungen in Krankheitsverständnis und Therapie

Der Onkologe, 2020-07, Vol.26 (7), p.661-672

2020

Volltextzugriff (PDF)

Multiples Myelom - dynamische Entwicklungen in Krankheitsverständnis und Therapie

Im Fokus Onkologie, 2020-11, Vol.23 (S1), p.21-31

2020

Volltextzugriff (PDF)

RAS mutations - for better or for worse in multiple myeloma?

Leukemia & lymphoma, 2016-01, Vol.57 (1), p.8-9

2016

Volltextzugriff (PDF)

Platelet Subpopulations and Distinct Platelet Function Defects after Hematopoietic Stem Cell Transplantation in Mice and Humans

Blood, 2023-11, Vol.142 (Supplement 1), p.348-348

2023

Volltextzugriff (PDF)

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Blood, 2023-11, Vol.142 (Supplement 1), p.3321-3321

2023

Volltextzugriff (PDF)

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.3293-3293

2023

Volltextzugriff (PDF)

P-351 Are genomic lesions of cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)?

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S232-S233

2023

Volltextzugriff (PDF)

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Blood, 2023-11, Vol.142 (Supplement 1), p.4186-4186

2023

Volltextzugriff (PDF)

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Blood, 2021-11, Vol.138 (Supplement 1), p.1587-1587

2021

Volltextzugriff (PDF)

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7076-7077

2022

Volltextzugriff (PDF)

P-248 CRISPR-Based Functional Genomics Studies Identify Mechanisms of Multiple Myeloma (MM) Cell Response to vs. Resistance Against Novel Pharmacological Mutant-Specific KRAS Inhibitors

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S180-S181

2024

Volltextzugriff (PDF)

68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms

The Journal of nuclear medicine (1978), 2022-01, Vol.63 (1), p.96-99

2022

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(54)

Sprache

Englisch
(50)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma

Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement

Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS

Efficient transient transfection of human multiple myeloma cells by electroporation--an appraisal

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma

JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen

JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen

Multiples Myelom – dynamische Entwicklungen in Krankheitsverständnis und Therapie

Multiples Myelom - dynamische Entwicklungen in Krankheitsverständnis und Therapie

RAS mutations - for better or for worse in multiple myeloma?

Platelet Subpopulations and Distinct Platelet Function Defects after Hematopoietic Stem Cell Transplantation in Mice and Humans

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

P-351 Are genomic lesions of cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)?

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

P-248 CRISPR-Based Functional Genomics Studies Identify Mechanisms of Multiple Myeloma (MM) Cell Response to vs. Resistance Against Novel Pharmacological Mutant-Specific KRAS Inhibitors

68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms

Suchergebnisse filtern